BridgeBio Pharma, Inc. (BBIO)

Market Cap	11.91B
Revenue (ttm)	353.78M
Net Income (ttm)	-797.12M
Shares Out	192.71M
EPS (ttm)	-4.18
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,326,272
Open	62.73
Previous Close	62.73
Day's Range	60.55 - 63.26
52-Week Range	21.72 - 69.48
Beta	1.27
Analysts	Strong Buy
Price Target	74.28 (+20.19%)
Earnings Date	Oct 29, 2025

About BBIO

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for t...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 27, 2019
• Employees: 730
• Stock Exchange: NASDAQ
• Ticker Symbol: BBIO
• Website: https://bridgebio.com

Financial Performance

In 2024, BridgeBio Pharma's revenue was $221.90 million, an increase of 2285.27% compared to the previous year's $9.30 million. Losses were -$535.76 million, -16.70% less than in 2023.

Analyst Summary

According to 18 analysts, the average rating for BBIO stock is "Strong Buy." The 12-month stock price target is $74.28, which is an increase of 20.19% from the latest price.

Price Target

$74.28

(20.19% upside)

Analyst Consensus: Strong Buy